| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
|
Medicine details |
|
| Medicine name | lanadelumab (Takhzyro®) |
| Formulation | 300 mg solution for injection |
| Reference number | 2884 |
| Indication | For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older |
| Company | Shire Pharmaceuticals Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/12/2018 |
| NICE guidance | TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |